Elsevier Inc.

SHERPA: Unknown

People

  1. Palomba
    Palomba
  2. Horwitz
    Horwitz
  3. Zelenetz
    Zelenetz
  4. Perales
    Perales
  5. Giralt
    Giralt
  6. Shah
    Shah
  7. Dahi
    Dahi
  8. Yahalom
    Yahalom
  9. Moskowitz
    Moskowitz
  10. Scordo
    Scordo

Groups

  1. Center for Hematologic Malignancies (187)
  2. Department of Medicine (187)
  3. Hematologic Malignancies, Division of (187)
  4. Lymphoma (187)
  5. Survivorship Research (70)
  6. Bone Marrow Transplant (43)
  7. Population Sciences Research Program (37)
  8. Epidemiology and Biostatistics (32)
  9. Biostatistics Service (29)
  10. CTCR Scholars (28)
Search Within
  1. "Lymphoma"
Formats
  1. Meeting Abstract (92)
  2. Journal Article (79)
  3. Editorial (7)
  4. Review (5)
  5. Conference Paper (2)
  6. Book Section (1)
  7. Guidelines (1)
Groups
  1. Center for Hematologic Malignancies (187)
  2. Department of Medicine (187)
  3. Hematologic Malignancies, Division of (187)
  4. Lymphoma (187)
  5. Survivorship Research (70)
  6. Bone Marrow Transplant (43)

More Groups

People
  1. Maria Palomba (44)
  2. Steven Horwitz (33)
  3. Craig Sauter (31)
  4. Andrew Zelenetz (30)
  5. Miguel-Angel Perales (29)
  6. Matthew Matasar (28)

More People

Years
  1. 2025 (3)
  2. 2024 (5)
  3. 2023 (7)
  4. 2022 (26)
  5. 2021 (17)
  6. 2020 (21)

More Years

Publications
  1. Clinical Lymphoma, Myeloma and Leukemia (63)
  2. Biology of Blood and Marrow Transplantation (38)
  3. International Journal of Radiation Oncology, Biology, Physics (18)
  4. Transplantation and Cellular Therapy (13)
  5. European Journal of Cancer (12)
  6. Hematology/Oncology Clinics of North America (8)

More Publications

Results (187)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Mosunetuzumab monotherapy demonstrates durable efficacy with a manageable safety profile in patients with relapsed/refractory follicular lymphoma who received ≥2 prior therapies: Updated results from a pivotal phase II study
    Meeting Abstract

    Bartlett, N. L.; Sehn, L. H.; Matasar, M.; Schuster, S. J.; Assouline, S.; Giri, P.; Kuruvilla, J.; Canales, M.; Dietrich, S.; Fay, K.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Lisocabtagene maraleucel (liso-cel) in R/R MCL: Primary analysis results from the mcl cohort of the single-arm, multicenter, phase I seamless design TRANSCEND NHL 001 study
    Meeting Abstract

    Palomba, M. L.; Siddiqi, T.; Gordon, L. I.; Kamdar, M.; Lunning, M.; Hirayama, A. V.; Abramson, J. S.; Arnason, J.; Ghosh, N.; Mehta, A.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • TRANSCEND FL: Phase II study results of lisocabtagene maraleucel (liso-cel) in patients with R/R follicular lymphoma (FL)
    Meeting Abstract

    Nastoupil, L. J.; Dahiya, S.; Palomba, M. L.; Garcia-Sancho, A. M.; Ortega, J. L. R.; Kuruvilla, J.; Jager, U.; Cartron, G.; Izutsu, K. I.; Dreyling, M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Future directions in the frontline management of Waldenström macroglobulinemia
    Review

    Buske, C.; Palomba, M. L.
    Hematology/Oncology Clinics of North America (2023)

    Fulltext@MSK | Save
  • Bridging radiation rapidly and effectively cytoreduces high-risk relapsed/refractory aggressive B cell lymphomas prior to chimeric antigen receptor T cell therapy
    Journal Article

    Hubbeling, H.; Silverman, E. A.; Michaud, L.; Tomas, A. A.; Shouval, R.; Flynn, J.; Devlin, S.; Wijetunga, N. A.; Tringale, K. R.; Batlevi, C.; more...
    Transplantation and Cellular Therapy (2023)

    Fulltext@MSK | Save
  • CD19-directed chimeric antigen receptor T cell therapy in Waldenström macroglobulinemia: Initial experience in two clinical trials
    Meeting Abstract

    Qualls, D.; Monette, S.; Sethi, S.; Dogan, A.; Roshal, M.; Senechal, B.; Wang, X.; Riviere, I.; Sadelain, M.; Brentjens, R.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Mosunetuzumab monotherapy is an effective and well-tolerated treatment option for patients with relapsed/refractory (R/R) follicular lymphoma (FL) who have received ≥2 prior lines of therapy: Pivotal results from a phase I/II study
    Meeting Abstract

    Budde, E. L.; Sehn, L. H.; Matasar, M.; Schuster, S. J.; Assouline, S.; Giri, P.; Kuruvilla, J.; Canales, M.; Dietrich, S.; Fay, K.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor in previously treated mantle cell lymphoma: Updated results from the phase 1/2 BRUIN study
    Meeting Abstract

    Cohen, J. B.; Shah, N. N.; Alencar, A. J.; Gerson, J. N.; Patel, M. R.; Fakhri, B.; Jurczak, W.; Tan, X. N.; Lewis, K. L.; Fenske, T.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • Primary efficacy and safety analysis of a global phase II study of zandelisib administered by intermittent dosing (ID) in patients with relapsed or refractory (R/R) follicular lymphoma (FL): The TIDAL study
    Meeting Abstract

    Phillips, T.; Jurczak, W.; Ribrag, V.; Linton, K.; Collin, G. P.; Lopéz-Jimenéz, J.; Reddy, N.; Mengarelli, A.; Musuraca, G.; Sheehy, O.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save
  • A SEER-Medicare analysis of the cost of disease progression after frontline R-CHOP in diffuse large B-cell lymphoma
    Meeting Abstract

    Burke, J. M.; Wang, R.; Hossain, F.; Li, J.; Masaquel, A.; Qiheng, S.; Matasar, M.
    Clinical Lymphoma, Myeloma and Leukemia (2022)

    Fulltext@MSK | Save